Beyond p-values: A phase II dual-criterion design with statistical significance and clinical relevance
暂无分享,去创建一个
Satrajit Roychoudhury | Beat Neuenschwander | Nicolas Scheuer | Satrajit Roychoudhury | B. Neuenschwander | N. Scheuer
[1] G. Casella,et al. Reconciling Bayesian and Frequentist Evidence in the One-Sided Testing Problem , 1987 .
[2] L. Wernisch,et al. An optimal stratified Simon two‐stage design , 2016, Pharmaceutical statistics.
[3] Heinz Schmidli,et al. A practical guide to Bayesian group sequential designs , 2014, Pharmaceutical statistics.
[4] J. Berger,et al. Testing a Point Null Hypothesis: The Irreconcilability of P Values and Evidence , 1987 .
[5] S. Steinberg,et al. Clinical trial designs for the early clinical development of therapeutic cancer vaccines. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] Terry M. Therneau,et al. Optimal two-stage screening designs for survival comparisons , 1990 .
[7] P Y Liu,et al. False positive rates of randomized phase II designs. , 1999, Controlled clinical trials.
[8] Christy Chuang-Stein,et al. The role of the minimum clinically important difference and its impact on designing a trial , 2011, Pharmaceutical statistics.
[9] Roland Fisch,et al. Bayesian Design of Proof-of-Concept Trials , 2015, Therapeutic innovation & regulatory science.
[10] J. French,et al. A Quantitative Approach for Making Go/No-Go Decisions in Drug Development , 2011 .
[11] W. Alan Nicewander,et al. A Consonance Criterion for Choosing Sample Size , 1997 .
[12] T R Fleming,et al. One-sample multiple testing procedure for phase II clinical trials. , 1982, Biometrics.
[13] Boris Freidlin,et al. Design issues of randomized phase II trials and a proposal for phase II screening trials. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] James Matcham,et al. Decision-making in early clinical drug development. , 2016, Pharmaceutical statistics.
[15] Peter Dalgaard,et al. R Development Core Team (2010): R: A language and environment for statistical computing , 2010 .
[16] Michael Branson,et al. A proof of concept phase II non‐inferiority criterion , 2011, Statistics in medicine.
[17] N. Lazar,et al. The ASA Statement on p-Values: Context, Process, and Purpose , 2016 .
[18] P Y Liu,et al. Selection designs for pilot studies based on survival. , 1993, Biometrics.
[19] Eric R. Ziegel,et al. Statistical Issues in Drug Development , 1997 .
[20] S K Carter,et al. Calibrated phase II clinical trials in oncology. , 1986, Statistics in medicine.
[21] R. Simon,et al. Optimal two-stage designs for phase II clinical trials. , 1989, Controlled clinical trials.
[22] D. Sargent,et al. A three-outcome design for phase II clinical trials. , 2001, Controlled Clinical Trials.
[23] S Madani,et al. Proof of Concept: A PhRMA Position Paper With Recommendations for Best Practice , 2010, Clinical pharmacology and therapeutics.
[24] R Simon,et al. Clinical trial designs for cytostatic agents: are new approaches needed? , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[25] B. Storer. A class of phase II designs with three possible outcomes. , 1992, Biometrics.